Trump Strikes Drug Deal With Regeneron
The Spin
Pro-Trump narrative
Every single one of the 17 pharmaceutical companies that got letters last year has now agreed to lower drug prices to most-favored-nation rates — and Regeneron is the latest to fall in line. Trump has delivered a massive win for American patients who've been paying way too much for way too long. The administration just proved that real pressure gets real results on health care affordability.
Anti-Trump narrative
These voluntary, company-by-company MFN deals are opaque, short-term and do nothing to fix the root causes of sky-high drug prices. Doctors overwhelmingly see TrumpRx as no better than GoodRx, with 54% calling it cosmetic and only 5% believing it tackles underlying pricing problems. Big Pharma still sets prices at will, and no amount of handshake agreements changes that dynamic.
